ViaCyte to Present at Four Upcoming Healthcare Events

SAN DIEGO, February 21, 2017 ViaCyte, Inc., a privately-held regenerative medicine company, today announced four presentations at upcoming healthcare events.  ViaCyte is advancing two novel cell replacement therapies as long-term diabetes treatments.  ViaCyte’s product candidates have the potential to provide a functional cure for patients with type 1 diabetes as well as an important therapy for patients with type 2 diabetes that depend on insulin to help control their disease.

Details of the presentations are as follows:

Event:                                   American Society of Transplantation – Cutting Edge of Transplantation Pipeline Session

Speaker:                              Dr. Kevin D’Amour, Vice President, Research and Chief Scientific Officer

Date/Time:                         February 23, 10:00 AM MST

Location:                              Arizona Biltmore, Phoenix


Event:                                   Keystone Engineered Cells and Tissues as Platforms for Discovery and Therapy

Speaker:                              Dr. Kevin D’Amour, Vice President, Research and Chief Scientific Officer

Date/Time:                         March 9, 8:30 AM EST

Location:                              Fairmont Copley Plaza, Boston


Event:                                   Center for Cell & Gene Therapy Series at Baylor College of Medicine

Speaker:                              Dr. Kevin D’Amour, Vice President, Research and Chief Scientific Officer

Date/Time:                         April 4, 9:00 AM EST

Location:                              Baylor College of Medicine, Houston


Event:                                   GTCbio 14th Stem Cell Research & Regenerative Medicine Summit

Speaker:                              Dr. Mark Zimmerman, Vice President, Strategy and Business Development

Date/Time:                         April 6, 8:30 AM EST

Location:                              Hyatt Regency, Boston


For more information about ViaCyte’s participation in industry events, please visit:


About ViaCyte

ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications.  ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells, which are then implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  ViaCyte has two products in development.  The PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients that have severe hypoglycemic episodes, extreme glycemic lability, and/or impaired hypoglycemia awareness.  The PEC-Encap (also known as VC-01) product candidate delivers pancreatic progenitor cells in an immunoprotective device designed to be administered without the need for chronic immunosuppression thus expanding the potential treatment to all patients that use insulin to control their disease.  ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.

For more information on ViaCyte, please visit and connect with ViaCyte here: and